Stock Analiz

Vertex Pharmaceuticals Inc. / MA (VRTX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Vertex Pharmaceuticals Inc. / MA’s revenue went from $1.7B in fiscal 2016 to $12.0B in fiscal 2025, growth of about 24.2% a year.

Net income in fiscal 2025 was $4.0B, a net margin of 32.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $13.0B and net income $4.0B.

Free cash flow was $3.2B in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count rose 5% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $1.7B162017: $2.5B172018: $3.0B182019: $4.2B192020: $6.2B202021: $7.6B212022: $8.9B222023: $9.9B232024: $11.0B242025: $12.0B25$12.0B
Net income
2016: -$112M162017: $263M172018: $2.1B182019: $1.2B192020: $2.7B202021: $2.3B212022: $3.3B222023: $3.6B232024: -$536M242025: $4.0B25$4.0B
Free cash flow
2016: $180M162017: $746M172018: $1.2B182019: $1.5B192020: $3.0B202021: $2.4B212022: $3.9B222023: $3.3B232024: -$790M242025: $3.2B25$3.2B
EPS (diluted)
2016: $-0.46162017: $1.04172018: $8.09182019: $4.51192020: $10.29202021: $9.01212022: $12.82222023: $13.89232024: $-2.08242025: $15.3225$15.32

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$13.0B$12.0B$11.0B$9.9B$8.9B$7.6B$6.2B$4.2B$3.0B$2.5B$1.7B
Gross profit$11.1B$10.3B$9.5B$8.6B$7.9B$6.7B$5.5B$3.6B$2.6B$2.2B$1.5B
Operating income$4.3B$4.2B-$233M$3.8B$4.3B$2.8B$2.9B$1.2B$635M$123M$10M
Net income$4.0B$4.0B-$536M$3.6B$3.3B$2.3B$2.7B$1.2B$2.1B$263M-$112M
EPS (diluted)$15.53$15.32$-2.08$13.89$12.82$9.01$10.29$4.51$8.09$1.04$-0.46
R&D$4.2B$3.9B$3.6B$3.2B$2.5B$3.1B$1.8B$1.8B$1.4B$1.3B$1.0B
Revenue growth—+8.9%+11.7%+10.5%+17.9%+22.1%+49.1%+36.6%+22.5%+46.2%+64.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$3.7B$3.6B-$493M$3.5B$4.1B$2.6B$3.3B$1.6B$1.3B$845M$236M
Capital spending-$492M-$438M-$298M-$200M-$205M-$235M-$260M-$75M-$95M-$99M-$57M
Free cash flow$3.2B$3.2B-$790M$3.3B$3.9B$2.4B$3.0B$1.5B$1.2B$746M$180M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$1.1B$2.0B$1.2B$428M$0$1.4B$539M$186M$350M$0$0
Stock-based pay$669M$686M$698M$581M$491M$441M$430M$360M$325M$293M$241M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$6.6B$6.1B$11.2B$10.8B$7.5B$6.7B$3.8B$3.2B$1.7B$1.2B
Debt—$1.9B$1.6B$382M$428M$411M$361M$96M—$0$300M
Equity—$18.7B$16.4B$17.6B$13.9B$10.1B$8.7B$6.1B$4.4B$2.0B$1.2B
Total assets—$25.6B$22.5B$22.7B$18.2B$13.4B$11.8B$8.3B$6.2B$3.5B$2.9B
Shares (diluted)255M258M258M260M259M260M263M261M259M253M245M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin85.5%86.2%86.1%87.2%87.9%88.1%88.1%86.8%86.6%88.9%87.6%
Operating margin33.2%34.8%-2.1%38.8%48.2%36.7%46.0%28.8%20.8%5.0%0.6%
Net margin30.7%32.9%-4.9%36.7%37.2%30.9%43.7%28.3%68.8%10.6%-6.6%
FCF margin24.7%26.6%-7.2%33.8%44.0%31.8%48.2%35.9%38.6%30.0%10.5%
ROIC—17.3%-1.0%17.6%23.6%22.7%27.5%16.3%11.3%4.8%0.5%
ROE—21.2%-3.3%20.6%23.9%23.2%31.2%19.3%47.3%13.0%-9.7%

Frequently asked questions

What is Vertex Pharmaceuticals Inc. / MA’s annual revenue?

$12.0B in fiscal 2025 and $13.0B over the twelve months to September 30, 2026.

How much profit does Vertex Pharmaceuticals Inc. / MA make?

Net income was $4.0B in fiscal 2025 (net margin 32.9%).

Is Vertex Pharmaceuticals Inc. / MA’s revenue growing?

Yes: revenue rose 8.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.